GlobeNews Wire

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin…

11 months ago

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio Connected Care Platform

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to…

11 months ago

Adaptec SmartRAID 4300 Series of Accelerators Deliver Scalable, Secure NVMe RAID Storage Solutions

CHANDLER, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- To better support server OEMs, storage systems, data centers and enterprise customers,…

11 months ago

Virtune AB (Publ) (“Virtune”) has completed the monthly rebalancing for July 2025 of its Virtune Crypto Top 10 Index ETP – the first crypto index ETP in the Nordics

August 05, 2025 07:04 ET  | Source: Virtune AB (Publ) Stockholm, 5 August 2025 - Virtune today announces the completion…

11 months ago

Xtract One Chosen by Volusia County Schools to Advance School Safety

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today…

11 months ago

CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune…

11 months ago

Tensive appointsmedical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Has more than 30 years of experience bringing innovations to market, including one of the world’s first drug-eluting coronary stents…

11 months ago

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…

11 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

August 04, 2025 08:05 ET  | Source: MaxCyte, Inc MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of…

11 months ago

Full Alliance Group Launches QUBEE HIVE HOLDINGS to Advance Global Web3 Financial Infrastructure

TAMPA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) today announced the formation of QUBEE…

11 months ago